New drug combination for untreated follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether three drugs (sonrotoclax, zanubrutinib, and rituximab) work together to treat follicular lymphoma in patients who have never received treatment before. The goal is to shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with follicular lymphoma (a type of blood cancer) and have never received treatment for it
- Your cancer is stage III or IV, or stage II with a large tumor mass
- You are at least 18 years old and generally well enough for treatment (ECOG score 0–2)
- You have adequate heart, lung, kidney, and liver function
- You are willing to use birth control if you can become pregnant, and you are not pregnant or breastfeeding
- You cannot take certain other medications that interact with the study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three targeted drugs (Orelabrutinib, Obinutuzumab, and Lenalidomide) against the standard approach for people with follicular lymphoma who haven't been treated yet. The goal is to see if the new drug combo works better and is safe.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a combination of three medications (orelabrutinib, tafasitamab, and lenalidomide) for newly diagnosed follicular lymphoma. The goal is to see if this combination can help control the cancer effectively.
This trial tests a new combination of targeted drugs (zanubrutinib, lenalidomide, and rituximab) against a standard two-drug combination for people with newly diagnosed follicular lymphoma who need treatment right away. It aims to see if the three-drug combo is more effective.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.